Financial Data and Key Metrics Changes - In Q2 2025, total revenue declined by 3.6%, with EBITDA and net profit decreasing by 1.6% and 3.8% respectively [27][28][33] - The EBITDA margin for Q2 was 41.6%, while the net profit margin was 30.4% [27][33] - For the first half of 2025, total revenue was down 4.6%, with a 5.3% decline in hospital operation revenue [30][33] Business Line Data and Key Metrics Changes - Revenue from non-Thai patients decreased by 6.6%, while Thai patient revenue slightly declined by 0.2% [27][30] - The outpatient service revenue contribution increased to 51% in the first half of 2025, up from 49% in the same period last year [31] - The government third-party contribution dropped to 14% from 18% in the first half of last year due to lower Middle East revenue [31] Market Data and Key Metrics Changes - Middle Eastern business showed strong growth, with Qatar up 18%, UAE up 46%, Oman up 28%, and Saudi Arabia up 54% [6][7] - The company experienced a decline in revenue from the Indo-China segment, particularly from Cambodia, which was offset by growth in Myanmar and Bangladesh [29][30] - The Chinese market saw a significant reduction in patient arrivals, down by over 30% to 40% year over year due to safety concerns [65][66] Company Strategy and Development Direction - The company is focusing on expanding its cancer care services and enhancing patient experience through new facilities and advanced technologies [88][92] - There is an emphasis on strengthening relationships with key stakeholders and third-party payers to drive growth [84] - The company aims to improve its market position by addressing governance issues and enhancing service quality for Kuwaiti patients [42][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q3 2025, expecting stronger performance compared to the first half of the year [18][26] - The company is cautiously optimistic about the return of Kuwaiti patients and the resolution of past payment issues [46][56] - Management highlighted the importance of addressing safety concerns to regain Chinese patient trust and increase medical tourism [66][70] Other Important Information - The company achieved recognition as one of the best specialized hospitals in Thailand across multiple specialties [77][78] - A successful disease screening campaign generated nearly 96 million baht in revenue within two months [80] - The company is actively investing excess cash into financial assets to capture higher interest income [34][35] Q&A Session Summary Question: What are the expectations for the Kuwaiti market? - Management indicated that discussions with Kuwaiti officials are ongoing, and there is cautious optimism about future collaborations and patient flow [46][56] Question: How is the company addressing the decline in Chinese patient arrivals? - The company is expanding its presence in China and engaging in targeted outreach to rebuild trust and increase referrals [66][70] Question: What are the key initiatives for cancer care expansion? - The company is focusing on comprehensive cancer care, integrating advanced technologies, and enhancing patient experience through new facilities [88][92]

Financial Data and Key Metrics Changes - The total revenue for Q2 2025 was 6,000 million baht, representing a decline of 3.6% year-over-year [26][27] - EBITDA margin reached a record high of 41.6%, while net profit margin was 30.4%, slightly up from 30.5% in the previous year [9][33] - EPS was reported at 40 baht, with a dividend payout ratio of 44% for the interim dividend, up from 41% the previous year [13] Business Line Data and Key Metrics Changes - Revenue from non-Thai patients decreased by 6.6%, while Thai patient revenue slightly declined by 0.2% [26][28] - The outpatient service revenue contribution increased to 51% from 49% in the first half of the previous year, while inpatient service revenue remained at 50% [31] - The MDA segment saw a significant decline of 12.4%, primarily from Qatar, Kuwait, and Oman, while the Indo-China segment increased by 0.4% [29][30] Market Data and Key Metrics Changes - Middle Eastern business showed strong growth, with Qatar up 18%, UAE up 46%, Oman up 28%, and Saudi Arabia up 54% [5][6] - The company experienced a decline in revenue from Chinese patients, with a drop of over 30% to 40% year-over-year due to safety concerns [65] - The Cambodian market is expected to stabilize, which could improve OPD footfalls and admissions in the future [66] Company Strategy and Development Direction - The company is focusing on expanding its cancer care services, recognizing the growing global cancer crisis and the need for comprehensive care [89][90] - Plans for a new cancer care facility are underway, aimed at enhancing patient experience and integrating advanced technologies [95] - The company is actively negotiating with the Kuwaiti government regarding patient payments and potential future collaborations [39][46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q3 2025, expecting stronger performance compared to the first half of the year [16][25] - The company is cautiously optimistic about the return of Kuwaiti patients, emphasizing the importance of quality care and governance [46][60] - The geopolitical situation in Cambodia and China is impacting patient flow, but management is hopeful for recovery in these markets [66][70] Other Important Information - The company received recognition from Newsweek as one of the best specialized hospitals in Thailand, ranking number one in six out of nine specialties [79] - A successful disease screening campaign generated nearly 96 million baht in revenue within two months [82] - The company upgraded its robotic surgery capabilities, expanding to more specialties and training additional surgeons [84] Q&A Session Summary Question: What is the outlook for the Kuwaiti market? - Management indicated that discussions with Kuwaiti officials are ongoing, and there is cautious optimism about future patient flow and payments [39][46] Question: How is the company addressing the decline in Chinese patients? - The company is expanding its presence in China and engaging in online outreach to improve connections with potential patients [67][68] Question: What are the expectations for the second half of 2025? - Management expects stronger performance in the second half compared to the first half, driven by recovery in key markets [16][25]

Financial Performance - Bumrungrad Hospital Public Company Limited's total revenues decreased by 3.6% in 2Q25 compared to 2Q24 and decreased by 4.6% in 1H25 compared to 1H24 [26, 27] - Net profit also experienced a decrease of 3.8% in 2Q25 compared to 2Q24 and a decrease of 8.3% in 1H25 compared to 1H24 [26, 36] - The EBITDA margin reached a company record of 41.6% in 2Q25 [5, 26, 34] - Non-Thai patient revenue decreased by 6.6% in 2Q25 and 8.2% in 1H25 compared to the same periods in the previous year [14, 21, 46, 50] Revenue Analysis - Middle East market share revenue increased by 23% compared to Q1 2025, with notable growth in Qatar (18%), UAE (46%), Oman (28%), and Saudi Arabia (54%) [5] - Non-Thai revenue has shown a CAGR of +5.8% from Y2018 to Y2024 [7] - Middle East non-Thai revenue increased by 56.2% from Y2018 to Y2024, while non-Middle East non-Thai revenue increased by 31.7% during the same period [10] - Inpatient and outpatient services contributed roughly equally to revenues, with inpatient services accounting for 50% in 2Q25 and 49% in 1H25 [29] Business Updates and Developments - Bumrungrad International Hospital has been recognized in Newsweek's Best Specialized Hospitals Asia Pacific 2025 ranking across all 9 specialty fields [52] - The hospital has been approved for renewal of its Advanced Hospital Accreditation (Advanced HA) under the Hospital and Healthcare Standards, with a certification period from May 23, 2025 – May 22, 2029 [55, 56] - A new Bumrungrad Comprehensive Cancer Center is under development, expected to be completed in 2027, with the aim of expanding capacity and enhancing patient experience [78, 80, 105]

Workplace Dynamics - Eight nurses at Lehigh Valley Hospital were pregnant within a few months of each other, fostering a unique bond [2] - The nurses, known as "PGO Floats," use a group chat for support and advice [3] - The group provided support for a nurse undergoing infertility treatments [3][4] - The nurses found the support invaluable during hospital shifts and the uncertainties of pregnancy [5] Human Resources & Employee Well-being - The hospital environment fostered a supportive community among colleagues [5] - The nurses plan to continue supporting each other through motherhood [6]

Core Points - FOXO Technologies Inc. announced that Big South Fork Medical Center has completed a Performance Network Agreement with Covenant Health to provide swing bed services [1][3] - The agreement aims to enhance post-acute care for patients who no longer meet acute care admission criteria, allowing them to recover closer to home [2][3] - The CEO of Big South Fork Medical Center emphasized the hospital's strategic location and service quality as key factors in attracting patients [3] Company Overview - FOXO Technologies Inc. operates three subsidiaries, including Rennova Community Health, which owns Big South Fork Medical Center, a critical access designated hospital [4] - Myrtle Recovery Centers, another subsidiary, provides behavioral health services, including inpatient detox and outpatient treatment programs [4] - FOXO Labs, Inc. focuses on biotechnology aimed at improving human health and lifespan through innovative technology [5]

Core Points - Select Medical Holdings Corporation reported a revenue increase of 4.5% to $1,339.6 million for Q2 2025 compared to Q2 2024 [2] - Income from continuing operations, net of tax, rose 53.8% to $57.9 million for Q2 2025 [2] - The company declared a cash dividend of $0.0625 per share, payable on August 28, 2025 [13] Financial Performance - For the six months ended June 30, 2025, revenue increased 3.4% to $2,692.8 million compared to the same period in the prior year [3] - Adjusted EBITDA for the six months was $276.9 million, down from $290.5 million in the prior year [3] - Earnings per common share from continuing operations increased 52.0% to $0.76 for the six months ended June 30, 2025 [3] Segment Performance - Critical Illness Recovery Hospital Segment revenue decreased to $601.1 million for Q2 2025, down from $604.9 million in Q2 2024 [6] - Rehabilitation Hospital Segment revenue increased 17.2% to $313.8 million for Q2 2025 compared to Q2 2024 [8] - Outpatient Rehabilitation Segment revenue increased 3.8% to $327.6 million for Q2 2025 compared to Q2 2024 [11] Stock Repurchase and Dividend - The Board of Directors authorized a stock repurchase program of up to $1.0 billion [15] - During the first half of 2025, Select Medical repurchased 6,375,512 shares at a cost of approximately $96.5 million [16] Business Outlook - Select Medical expects revenue for fiscal year 2025 to be in the range of $5.3 billion to $5.5 billion [17] - Adjusted EBITDA is projected to be between $510.0 million and $530.0 million for 2025 [17]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation due to allegations of violations of federal securities laws and unlawful business practices following negative reports about the company's hospital performance [1][3]. Group 1: Allegations and Impact - A New York Times article published on July 15, 2025, reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of potentially preventable readmissions [3]. - The article highlighted "alarming mistakes" that have led to patient fatalities, raising serious concerns about the company's operational practices [3]. - Following the publication of this article, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share, resulting in financial losses for investors [4]. Group 2: Legal Actions and Contact Information - Investors who purchased or acquired Encompass shares and suffered losses are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims [1][5]. - The law firm specializes in representing individual and institutional investors in complex litigation, indicating a focus on protecting shareholder interests [6].

Financial Data and Key Metrics Changes - The company reported net income attributable to UHS per diluted share of $5.43 for Q2 2025, with adjusted net income per diluted share at $5.35 after adjustments [5][6] - Adjusted admissions to acute care hospitals increased by 2% year-over-year, while surgical volumes decreased slightly [5] - Same facility net revenues in the acute care hospital segment increased by 5.7% compared to Q2 2024, excluding the impact of the insurance subsidiary [5][6] - Cash generated from operating activities decreased by $167 million to $9 million in Q2 2025 compared to $1,076 million in Q2 2024 [8] - The company repurchased approximately 1.9 million shares at a total cost of about $332 million since 2019, representing 34% of outstanding shares [9] Business Line Data and Key Metrics Changes - Same facility net revenues at behavioral health hospitals increased by 5.4%, driven by a 4.2% increase in revenue per adjusted day [7] - Adjusted patient days in behavioral health were up 1.2% compared to the prior year's second quarter [8] - Operating expenses on a same facility basis increased by 3.1% year-over-year, excluding the impact of the insurance subsidiary [6] Market Data and Key Metrics Changes - The company noted a cannibalization impact on same facility volumes and revenues from the newly opened West Henderson Hospital [6] - The performance of the Las Vegas and District of Columbia markets showed some economic softness, impacting overall volumes [91] Company Strategy and Development Direction - The company is focusing on outpatient growth, aiming to capture a larger share of the outpatient behavioral care market [25][26] - New developments include a 96-bed behavioral hospital in Grand Rapids, Michigan, and a 41-bed substance use disorder treatment center in South Carolina, among others [12][13] - The company is also expanding its Signet Behavioral Health Network in the UK, adding six new facilities and 137 beds [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in adapting to potential Medicaid revenue reductions starting in 2028, emphasizing strategic shifts in the behavioral business [17][19] - The company anticipates that the impact of the One Beautiful Bill Act on Medicaid revenues will be manageable, with ongoing discussions with state representatives [20][21] - Management acknowledged challenges in the startup of Cedar Hill Regional Medical Center but remains optimistic about long-term prospects [11][30] Other Important Information - The company spent $5 million on capital expenditures in 2025, with 25% allocated to new replacement facilities in California and Florida set to open in 2026 [8] - The company has approximately $1 billion of available borrowing capacity under its revolving credit facility [9] Q&A Session Summary Question: Impact of Medicaid changes on EBITDA - Management indicated that reductions from Medicaid changes will not begin until 2028, allowing time to adjust business strategies, particularly in the behavioral segment [17][18] Question: Behavioral patient days split - Management noted that adjusted patient days have grown faster than unadjusted patient days, indicating outpatient growth is a significant opportunity [24][25] Question: Update on Cedar Hill's accreditation status - Management acknowledged startup losses of $25 million in Q2 for Cedar Hill, with another $25 million expected in the second half of the year, pending Medicare certification [30] Question: Behavioral pricing growth - Management confirmed that behavioral pricing growth has outperformed expectations, with a breakdown of 4.2% increase in pricing and 1.2% in adjusted patient days [50][52] Question: Long-term margin targets - Management expressed confidence in maintaining long-term margin targets despite upcoming challenges, emphasizing flexibility in programming adjustments [96][98] Question: Labor market challenges - Management reported that while wage inflation has decelerated, staffing challenges persist in certain markets, particularly in behavioral health [68][70]

Financial Data and Key Metrics Changes - The company reported net income attributable to UHS per diluted share of $5.43 for Q2 2025, with adjusted net income per diluted share at $5.35 after adjustments [4][6] - Adjusted admissions to acute care hospitals increased by 2% year-over-year, while surgical volumes decreased slightly [4] - Same facility net revenues in the acute care hospital segment increased by 5.7% compared to Q2 2024, excluding the impact of the insurance subsidiary [4] - Cash generated from operating activities decreased by $167 million to $909 million in Q2 2025 compared to $1,076 million in Q2 2024 [6] - The company spent $500 million on capital expenditures, with 25% allocated to new replacement facilities in California and Florida [6] Business Line Data and Key Metrics Changes - Same facility EBITDA increased by 10% in the acute care segment, driven by solid revenue and effective expense controls [5] - In the behavioral health segment, same facility net revenues increased by 5.4%, with a 4.2% increase in revenue per adjusted day [5] - Adjusted patient days in the behavioral health segment were up 1.2% compared to the prior year's second quarter [6] Market Data and Key Metrics Changes - The West Henderson Hospital, opened in late 2024, had a cannibalization impact on same facility volumes and revenues [5] - The company noted a slight decrease in surgical volumes, indicating potential market challenges [4] Company Strategy and Development Direction - The company is increasing its EPS guidance for 2025 by 7% to $20.50 per diluted share, driven by increased DPP reimbursement [10] - The company is focusing on outpatient growth in the behavioral segment, with plans to open 10-15 new outpatient facilities annually [42] - The company is developing new behavioral health hospitals in various locations, including Michigan and Pennsylvania, to expand its service offerings [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term prospects for the Cedar Hill Regional Medical Center despite initial startup challenges [11] - The company anticipates potential changes to Medicaid programs that could impact future revenues, with a projected reduction in net benefits starting in 2028 [8] - Management emphasized the ability to pivot and adapt to changes in the operating environment, drawing on past experiences during the pandemic [17][20] Other Important Information - The company repurchased approximately 1.9 million shares at a cost of $332 million since 2019, representing about 34% of outstanding shares [7] - The One Beautiful Bill Act includes significant changes to the Medicaid program, which may impact future revenues [8] Q&A Session Summary Question: Impact of Medicaid changes on EBITDA - Management confirmed the projected reduction of $360 million to $400 million in net benefits starting in 2028, with strategies to offset this through operational adjustments [15][17] Question: Behavioral health volume growth - Management noted that outpatient growth is a significant opportunity, with adjusted patient days growing faster than inpatient days [21][24] Question: Cedar Hill's startup losses - Management acknowledged $25 million in startup losses for Cedar Hill in Q2, with another $25 million expected in the second half of the year, but expressed optimism for future profitability [26][30] Question: Outpatient behavioral growth strategy - Management detailed plans to enhance outpatient services through step-down and step-in business models, aiming to capture a larger share of the outpatient market [38][42] Question: Labor market challenges - Management indicated that while wage inflation has slowed, staffing challenges persist, particularly in the behavioral segment [66][68] Question: DPP program updates - Management provided updates on ongoing discussions with CMS regarding the approval of DPP programs, emphasizing the potential for new programs despite legislative changes [70][72]

Core Viewpoint - The Hainan Provincial Health Commission is enhancing the service quality of the 12345 hotline to address public medical needs more effectively, ensuring that patient complaints and inquiries are handled promptly and efficiently [2][4]. Group 1: Service Improvement Measures - The establishment of a Medical Service Supervision Group at the Provincial People's Hospital aims to address patient inquiries and complaints directly, implementing a "first contact responsibility" system to ensure accountability [3][4]. - The hotline operates 24/7, and a new complaint management method was introduced, which includes clear processing norms and timelines, linking performance assessments to the handling of complaints [3][5]. - The number of complaints decreased from 966 to 649 between March and June, reflecting a monthly decline rate of 12.35%, with a 15.40% decrease in complaints through the 12345 platform [3][5]. Group 2: Systematic Changes and Future Plans - The Provincial Health Commission is pushing for a comprehensive optimization of medical service processes across the province, focusing on improving the quality of healthcare services and transforming the industry’s work ethic [4][5]. - The commission plans to enhance the capabilities of hotline staff and improve the quality management of the complaint handling process, integrating data analytics and AI to proactively address common issues [5].